Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10397159rdf:typepubmed:Citationlld:pubmed
pubmed-article:10397159lifeskim:mentionsumls-concept:C0024880lld:lifeskim
pubmed-article:10397159lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:10397159lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:10397159lifeskim:mentionsumls-concept:C0162825lld:lifeskim
pubmed-article:10397159lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:10397159pubmed:issue1lld:pubmed
pubmed-article:10397159pubmed:dateCreated1999-10-21lld:pubmed
pubmed-article:10397159pubmed:abstractTextMucosal type mast cells, in contrast to the serosal type ones, do not respond to cationic agents, or to the complement-derived peptides C3a and C5a. Earlier we have found that while C3a does not activate the rat mucosal type mast cells (line RBL-2H3), it strongly inhibits the IgE-mediated triggering of these cells, by interfering with the Fc epsilon RI-initiated signaling pathway. In the present study we further investigated the mechanism of this process. It is shown, that C3a interacts with the beta-chain of the Fc epsilon RI complex. Binding of the complement peptide to the cells apparently causes a decrease in the proximity of the IgE-binding Fc epsilon RI. Investigating certain sequences of C3a we found that the inhibition is caused by the C-terminal sequences of the complement-peptide, ranging from positions 56 to 77 and also by a shorter sequence, ranging from positions 56 to 64. The inhibitory effect of these peptides was observed both in the case of RBL-2H3 cells and mouse bone marrow derived mast cells.lld:pubmed
pubmed-article:10397159pubmed:languageenglld:pubmed
pubmed-article:10397159pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10397159pubmed:citationSubsetIMlld:pubmed
pubmed-article:10397159pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10397159pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10397159pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10397159pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10397159pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10397159pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10397159pubmed:statusMEDLINElld:pubmed
pubmed-article:10397159pubmed:monthMaylld:pubmed
pubmed-article:10397159pubmed:issn0165-2478lld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:PechtIIlld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:ErdeiAAlld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:MatkóJJlld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:BeneLLlld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:BajtayZZlld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:RongXXlld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:TóthG KGKlld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:IschenkoAAlld:pubmed
pubmed-article:10397159pubmed:authorpubmed-author:AndrásfalvyMMlld:pubmed
pubmed-article:10397159pubmed:issnTypePrintlld:pubmed
pubmed-article:10397159pubmed:day3lld:pubmed
pubmed-article:10397159pubmed:volume68lld:pubmed
pubmed-article:10397159pubmed:ownerNLMlld:pubmed
pubmed-article:10397159pubmed:authorsCompleteYlld:pubmed
pubmed-article:10397159pubmed:pagination79-82lld:pubmed
pubmed-article:10397159pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:meshHeadingpubmed-meshheading:10397159...lld:pubmed
pubmed-article:10397159pubmed:year1999lld:pubmed
pubmed-article:10397159pubmed:articleTitleInhibition of IgE-mediated triggering of mast cells by complement-derived peptides interacting with the Fc epsilon RI.lld:pubmed
pubmed-article:10397159pubmed:affiliationDepartment of Immunology, Loránd Eötvös University, Göd, Hungary. erdann@alfa.elte.hulld:pubmed
pubmed-article:10397159pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10397159pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed